熊去氧胆酸治疗婴儿胆汁淤积型巨细胞病毒性肝炎的临床评价

摘要

Objective: To study the effect and safety of UDCA (Ursodeoxycholic acid) capsule treatment for infantile CMV hepatitis with cholestasis.Method: 40 pediatric patients were divided into 2 groups: 20 cases in UDCA group, 20 cases in control group. Both of the 2 groups were given routine therapy including antiviral therapy, improvement of liver functions and comprehensive treatment. UDCA was used in treatment of patients in trial group in addition to the routine therapy. Their clinical features and the levels of serum ALP, GGT, TBIL, et al, were evaluated and compared. The therapeutic effect were assessed and compared after taking drugs for 2 weeks.Result: Levels of ALP, GGT, TBIL, DBIL, TBA, AKP, GGT in each of the 2 groups decreased significantly(P<0.05). The levels of TBIL and DBIL significantly decreased in the UDCA group (P<0.05).Conclusion: UDCA capsule can promote bile acid excretion, accelerate the jaundice subsided, improve liver function biochemical parameters of infantile CMV hepatitis with cholestasis. It is safe and effective without obvious adverse reactions. It is worth promoting.%目的：观察熊去氧胆酸（UDCA）治疗婴儿胆汁淤积型巨细胞病毒性（CMV）肝炎的疗效及安全性。方法：40例患儿按随机数字表法分为UDCA治疗组20例与对照组20例，两组病例均予抗病毒、保肝及综合治疗。治疗组在此基础上加用UD，观察临床表现及肝生化指标，判断药物疗效。结果：治疗2周后观察患儿氨酸ALT、总胆红素TBIL、总胆汁酸TBA、碱性磷酸酶AKP、谷氨酰转肽酶GGT水平均较治疗前下降，差异具有统计学意义（P<0.05）。加用UDCA治疗组TBA、TBIL下降明显，优于对照组（P<0.05）。结论：对于婴儿胆汁淤积型CMV肝炎，辅助应用UDCA，促进胆汁酸排泄、加速黄疸消退，改善肝功能，且无明显不良反应，安全有效，值得推广。